Although the reason for treatment failure is complex, it is related to the insufficient numbers of T cells or poorly functioning pre-existing T cells (due to epigenetic dysfunction or the acquisition of other immunosuppressive signals), disruption of antigen presentation that leads to decreased T cell recognition of the tumor, primary resistance to IFN-γ signaling, and the immunosuppressive tumor microenvironment [3, 10] Long-term use of PD-L1 inhibitors can also lead to the occurrence of immune-related adverse events such as humoral autoimmunity [11]. This evidence concerns the gene IFNG and neoplasm.